The AHA and six other organizations today submitted comments to the Drug Enforcement Administration on its proposed rule regarding controlled substances quotas. “Although we support DEA’s efforts to combat diversion, we are concerned that the proposed rule is focused on diversion to the exclusion of another critical factor — drug shortages,” the AHA and other groups wrote. “To ensure that legitimate medical needs are met, it is imperative that drug shortages be considered as aggregate production quotas are set and adjusted.” The letter also was signed by the Ambulatory Surgical Center Association, American Society of Clinical Oncology, American Society of Health-System Pharmacists, American Society of Anesthesiologists, Federation of American Hospitals, and Institute for Safe Medication Practices. The AHA last week submitted its own letter to DEA urging the agency to explicitly consider drug shortages when setting and adjusting aggregate production quotas, citing concern that the agency's proposal to reduce 2020 production quotas for five opioid controlled substances would exacerbate shortages of injectable opioid medications.

Related News Articles

Insights and Analysis
Many hospitals and health systems are reducing costs and improving health outcomes by addressing disparities head on, write Priya Bathija, vice president of…
Headline
The AHA’s Society for Health Care Strategy & Market Development has chosen as its 2020 President-elect Jennifer Weiss Wilkerson.
Headline
AHA Chair-elect Melinda Estes, M.D., president and CEO of Saint Luke’s Health System in Kansas City, gave a keynote today at the 43rd World Hospital Congress…
Headline
Crain’s Chicago Business this week named Priya Bathija, vice president of AHA’s The Value Initiative, to its list of Notable Women in Health Care.
Headline
The AHA, Association of American Medical Colleges and several member hospitals intend to immediately request that the U.S. District Court for the District of…
Headline
The AHA this week encouraged the Centers for Medicare…